| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5701499 | Journal of Thoracic Oncology | 2017 | 18 Pages |
Abstract
Alectinib is a treatment option for patients with ALK rearrangement-positive NSCLC and a poor PS.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Eiji MD, PhD, Yasushi MD, PhD, Haruyasu MD, PhD, Taishi MD, PhD, Shinsuke MD, Hiroyuki MD, PhD, Yoshiaki MD, PhD, Noriaki MD, Yuka MD, PhD, Masahiro MD, PhD, Akihiro MD, PhD, Manabu MD, PhD, Akihito MD, Hiroaki MD, Ryotaro MD, Shinichiro MD,